NCT03254004 2020-12-14Postoperative Pembrolizumab for the Patients Who Have Solid Predominant or Micropapillary Lung Adenocarcinoma With Pathologic Stage I and Primary Tumor Than 4 cmSamsung Medical CenterPhase 2 Unknown70 enrolled